RNAi in arthritis: prospects of a future antisense therapy in inflammation.
Rheumatoid arthritis is a chronic autoimmune disease of unknown etiology that is characterized by chronic systemic inflammation, mainly affecting the joints, leading to subsequent destruction of the cartilage and bone. RNA interference (RNAi) has been used as a remarkable new research tool to control gene expression and is ultimately envisioned to be useful in clinical treatments. The potential application of RNAi-based therapy in rheumatoid disorders is evaluated. The first successful attempts at TNFalpha silencing by local and systemic delivery of small interfering RNA in experimental arthritic models are discussed. In addition, RNAi and current biotherapies used in the clinic are compared and contrasted.
Khoury
Maroun
M
Inserm U 844, INM Hôpital Saint Eloi, BP 74103, 80 rue Augustin Fliche, 34091 Montpellier cedex 5, France. khoury@montp.inserm.fr
Jorgensen
Christian
C
Apparailly
Florence
F
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D005544:Forecasting; D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology / Q000627:therapeutic use*; D034622:RNA Interference / Q000502:physiology*; D016372:RNA, Antisense / Q000627:therapeutic use*; D034741:RNA, Small Interfering / Q000627:therapeutic use
D018836:Inflammation Mediators; D016372:RNA, Antisense; D034741:RNA, Small Interfering